Evaluating the Diagnostic Performance of (HRCT) in IPD Fibrosis in Suspected Cases

NCT ID: NCT07048652

Last Updated: 2025-07-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

68 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-03-17

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This will be a cross-sectional descriptive study aimed at evaluating the role of high-resolution computed tomography (HRCT) in diagnosing Idiopathic Pulmonary Fibrosis (IPF).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Pulmonary Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High-Resolution Computed Tomography

High-resolution computed tomography (HRCT) plays a crucial role in diagnosing and managing Idiopathic Pulmonary Fibrosis (IPF). It helps identify the characteristic pattern of IPF, known as Usual Interstitial Pneumonia (UIP), and can sometimes obviate the need for lung biopsy.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 years and above.
* Patients clinically suspected of having IPF.
* Patients referred for HRCT examination.
* Patients who provide informed consent to participate in the study.

Exclusion Criteria

* Patients with a known diagnosis of other interstitial lung diseases.
* Patients with comorbid conditions that could mimic IPF.
* Patients who are pregnant.
* Patients with incomplete medical records or imaging studies
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Superior University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Muhammad Naveed Babur

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AYK Hospital

Lahore, , Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MSAHSW/Batch-Fall23/905

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Disease-syndrome Characteristics of IPF
NCT07178392 NOT_YET_RECRUITING